Suchen
Uniqure NV
QUREZur Watchlist hinzufügen
45.170USD
-0.890-1.93%
Handelsschluss 07/01, 16:00（ET）Kurse um 15 Minuten verzögert
2.85BMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Uniqure NV Unternehmen
Uniqure NV is a company based in the Netherlands specialized in gene therapy. It seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. It develops, both internally and through partnerships, a pipeline of gene therapies. It produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.
Uniqure NV Informationen
BörsenkürzelQURE
Name des UnternehmensUniqure NV
IPO-datumFeb 05, 2014
CEOKapusta (Matthew)
Anzahl der mitarbeiter209
WertpapierartOrdinary Share
GeschäftsjahresendeFeb 05
AddressePaasheuvelweg 25a
StadtAMSTERDAM
BörseNASDAQ OMX - NASDAQ BASIC
LandNetherlands
Postleitzahl1105 BP
Telefon31202406000
Websitehttps://www.uniqure.com/
BörsenkürzelQURE
IPO-datumFeb 05, 2014
CEOKapusta (Matthew)
Führungskräfte von Uniqure NV
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Christian Klemt, CPA
Mr. Christian Klemt, CPA
Chief Financial Officer
Chief Financial Officer
121.51K
+23.43%
Walid Abi-Saab
Walid Abi-Saab
Chief Medical Officer
Chief Medical Officer
63.73K
-31.38%
Dr. Robert Gut, M.D., Ph.D.
Dr. Robert Gut, M.D., Ph.D.
Non-Executive Director
Non-Executive Director
47.69K
-0.17%
Dr. Jeannette Potts, J.D., Ph.D.
Dr. Jeannette Potts, J.D., Ph.D.
Chief Legal and Compliance Officer and Corporate Secretary
Chief Legal and Compliance Officer and Corporate Secretary
42.31K
-12.38%
Mr. Madhavan (Madhu) Balachandran
Mr. Madhavan (Madhu) Balachandran
Non-Executive Independent Director
Non-Executive Independent Director
35.28K
+15.75%
Dr. Jeremy P. Springhorn, Ph.D.
Dr. Jeremy P. Springhorn, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
35.28K
+15.75%
Dr. Leonard E. Post, Ph.D.
Dr. Leonard E. Post, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
27.52K
+20.19%
Ms. Rachelle Suzanne Jacques
Ms. Rachelle Suzanne Jacques
Non-Executive Independent Director
Non-Executive Independent Director
25.93K
+21.43%
Mr. Jack L. Kaye, CPA
Mr. Jack L. Kaye, CPA
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. David Meek
Mr. David Meek
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Christian Klemt, CPA
Mr. Christian Klemt, CPA
Chief Financial Officer
Chief Financial Officer
121.51K
+23.43%
Walid Abi-Saab
Walid Abi-Saab
Chief Medical Officer
Chief Medical Officer
63.73K
-31.38%
Dr. Robert Gut, M.D., Ph.D.
Dr. Robert Gut, M.D., Ph.D.
Non-Executive Director
Non-Executive Director
47.69K
-0.17%
Dr. Jeannette Potts, J.D., Ph.D.
Dr. Jeannette Potts, J.D., Ph.D.
Chief Legal and Compliance Officer and Corporate Secretary
Chief Legal and Compliance Officer and Corporate Secretary
42.31K
-12.38%
Mr. Madhavan (Madhu) Balachandran
Mr. Madhavan (Madhu) Balachandran
Non-Executive Independent Director
Non-Executive Independent Director
35.28K
+15.75%
Dr. Jeremy P. Springhorn, Ph.D.
Dr. Jeremy P. Springhorn, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
35.28K
+15.75%
Häufig gestellte Fragen
Wer sind die fünf größten Anteilseigner von Uniqure NV?
Die fünf größten Anteilseigner von Uniqure NV sind: Mr. Christian Klemt, CPA
Wie viele Institutionen halten Anteile an Uniqure NV (QURE)?
Mit Stand vom 2026Q1 halten 481 Institutionen Anteile an Uniqure NV, mit einem Gesamtmarktwert von etwa 65.80M, was 104.34% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um 1601871.00 gestiegen.